Anzeige
Mehr »
Login
Mittwoch, 30.10.2024 Börsentäglich über 12.000 News von 675 internationalen Medien
Desert Gold Ventures: Diese Goldaktie ist ein TOP-Übernahmekandidat
Anzeige

Indizes

Kurs

%
News
24 h / 7 T
Aufrufe
7 Tage

Aktien

Kurs

%
News
24 h / 7 T
Aufrufe
7 Tage

Xetra-Orderbuch

Fonds

Kurs

%

Devisen

Kurs

%

Rohstoffe

Kurs

%

Themen

Kurs

%

Erweiterte Suche

WKN: A14TVM | ISIN: SE0007100581 | Ticker-Symbol: ALZC
Tradegate
29.10.24
17:47 Uhr
29,260 Euro
-0,020
-0,07 %
1-Jahres-Chart
ASSA ABLOY AB Chart 1 Jahr
5-Tage-Chart
ASSA ABLOY AB 5-Tage-Chart
RealtimeGeldBriefZeit
29,15029,23008:25
29,13029,21008:23
PR Newswire
311 Leser
Artikel bewerten:
(2)

Assa Abloy Quarterly Report Q2 2024

STOCKHOLM, July 17, 2024 /PRNewswire/ --

Strong performance

Second quarter

  • Net sales increased by 10% to SEK 37,968 M (34,474), with organic growth of -1% (3) and acquired net growth of 11% (6). Exchange- rates affected sales by 0% (8).
  • Organic sales growth was good in Americas and EMEIA, stable in Entrance Systems, but declined in Asia Pacific and Global Technologies.
  • Eight acquisitions with combined annual sales of about SEK 1,000 M were completed in the quarter.
  • Operating income1 (EBIT) increased by 11% and amounted to SEK 6,085 M (5,500), with an operating margin of 16.0% (16.0).
  • Net income1 amounted to SEK 3,927 M (3,731).
  • Earnings per share1 amounted to SEK 3.54 (3.36).
  • Operating cash flow amounted to SEK 5,604 M (6,671).

Sales and income


Second quarter




First half-year



2023

2024


?


2023

2024

?

Sales, SEK M

34,474

37,968


10 %


66,865

73,168

9 %

Of which:









Organic growth

897

-349


-1%


3,115

-1,111

-2 %

Acquisitions and divestments

2,002

3,925


11 %


3,346

7,532

11 %

Exchange-rate effects

2,109

-83


0 %


4,346

-118

0 %

Operating income (EBIT)1, SEK M

5,500

6,085


11 %


10,686

11,512

8 %

Operating margin (EBITA)1, %

16.6 %

16.9 %




16.6 %

16.6 %


Operating margin (EBIT)1, %

16.0 %

16.0 %




16.0 %

15.7 %


Income before tax1, SEK M

5,054

5,236


4 %


9,898

9,852

0 %

Net income1, SEK M

3,731

3,927


5 %


7,423

7,389

0 %

Operating cash flow, SEK M

6,671

5,604


-16%


10,741

8,701

-19%

Earnings per share1, SEK

3.36

3.54


5 %


6.68

6.65

0 %

1 Excluding items affecting comparability. Please see the "Items affecting comparability" section in the report for further details about the financial effects in 2024. For information about items affecting comparability in 2023, please see the Year-end report 2023, available at assaabloy.com.

Comments by the President and CEO

Strong performance
Today we announce strong results in a challenging market environment. Our sales grew 10%, driven by very strong acquired net growth of 11%, while organic sales declined 1% and the operating margin was strong at 16.0%. The continued solid non-residential development in the US contributed to good organic sales growth of 3% in the Americas division while EMEIA's organic sales grew 1%. In Entrance Systems, organic sales were flat, where much lower demand for loading docks in the US were offset by strong growth in Pedestrian. Organic sales in Asia Pacific and Global Technologies declined by 5% and 7% respectively. The decline in Asia Pacific was mainly because of continued low construction activity in China, while high comparable sales figures last year due to the backlog catchup in Physical Access Control remained a challenge for Global Technologies.

The operating profit increased by 11% to SEK 6,085 M, corresponding to an operating margin of 16.0%. Strong operational execution through implementation of cost actions of about SEK 300 M, continued strong price realization, lower direct material costs and HHI contributed to the strong bottom line performance. The operating cash flow was excellent in the quarter, SEK 5,604 M, with a cash conversion of 107%.

Acquired growth is a key pillar for our growth strategy
To deliver on our 10% annual growth target we work with strategic activities shared across our divisions. One of these activities is to continue our acquisition journey. This has been a vital part of our strategy since the foundation, and it is further underscored by the strong growth in the first half of 2024. After a record of 24 acquisitions in 2023, we have closed another 11 acquisitions in the first six months of 2024. Given our robust pipeline and strong financial performance, we can continue our successful acquisition strategy. We are also convinced that the combination of our well-structured M&A process, our local knowledge and clear-cut investment criteria, provide a solid base for continued synergy realization while also enabling accelerated organic growth over time.

This report marks the one-year anniversary of ASSA ABLOY becoming the proud owner of HHI. Since the consolidation last year, I've had the opportunity to visit most of HHI's facilities and factories. This has left me with a very good impression of the operations, the HHI team and all the opportunities going forward. The integration of HHI continues according to plan and we are even more confident than a year ago that we will be able to realize USD 100 M in synergies. It is also encouraging that HHI, on a standalone basis in the quarter, delivered a high-single digit sales growth with a sequentially improved operating margin. We are confident that this positive trend will continue.

We can look back on a strong financial performance in the first half of 2024 and I am convinced that the Group is in an excellent position to continue to lead the industry and generate significant value for all our stakeholders.

Stockholm, July 17, 2024

Nico Delvaux
President and CEO

Further information can be obtained from:

Nico Delvaux,
President and CEO, tel. no: +46 8 506 485 82

Erik Pieder,
Executive Vice President and CFO, tel.no: +46 8 506 485 72

Björn Tibell,
Head of Investor Relations, tel. no: +46 70 275 67 68, e-mail: bjorn.tibell@assaabloy.com

ASSA ABLOY is holding a telephone and web conference at 09.00 on July 17, 2024 which can be followed online at assaabloy.com/investors.

It is possible to submit questions by telephone on: 08-505 100 31, +44 207 107 0613 or +1 631 570 5613

This information is information that ASSA ABLOY AB is obliged to make public pursuant to the EU Market Abuse Regulation and the Securities Markets Act. The information was submitted for publication, through the agency of the contact persons set out above, at 08.00 CEST on July 17, 2024.

This information was brought to you by Cision http://news.cision.com

https://news.cision.com/assa-abloy/r/quarterly-report-q2-2024,c4015788

The following files are available for download:

https://mb.cision.com/Main/7333/4015788/2918795.pdf

The full report (PDF)

https://news.cision.com/assa-abloy/i/assa-abloy-logo-door,c3320441

ASSA ABLOY logo door

Cision View original content:https://www.prnewswire.co.uk/news-releases/assa-abloy-quarterly-report-q2-2024-302199105.html

© 2024 PR Newswire
Tenbagger-Chance mit der nächsten BioNTech

Erinnern Sie sich, als Moderna und BioNTech von unbekannten Unternehmen zu globalen Marktführern wurden und frühzeitige Investoren reich belohnt haben?

Die Branche steht vor einem erneuten Innovationsschub – von bahnbrechenden Medikamenten bis hin zu revolutionären Therapien.

Warum sollten Sie dabei sein?

Sie sollten jetzt in Biotech-Aktien einsteigen, weil wir am Beginn einer neuen Ära der medizinischen Innovation stehen könnten! Gen- und Zelltherapien, personalisierte Medizin und bahnbrechende Technologien könnten das Gesundheitswesen revolutionieren – und die Aktienkurse in die Höhe schießen lassen.

Die nächste Erfolgsgeschichte im Biotechbereich warten nur darauf, entdeckt zu werden. Wer jetzt investiert, hat die Chance, von gigantischen Durchbrüchen und enormen Renditen zu profitieren. Warten Sie nicht, bis es zu spät ist - der nächste Biotech-Superstar könnte morgen schon durchstarten!

Verpassen Sie nicht diese Chance!

Fordern Sie sofort unseren brandneuen Biotech-Spezialreport an und erfahren Sie, welche 3 Biotech-Aktien das riesige Potenzial haben, Ihren finanziellen Erfolg zu sichern. Dieser Report ist komplett kostenlos und zeigt Ihnen zukunftsträchtige Investments im Biotech-Sektor.

Handeln Sie jetzt und sichern Sie sich Ihren kostenfreien Report!

Werbehinweise: Die Billigung des Basisprospekts durch die BaFin ist nicht als ihre Befürwortung der angebotenen Wertpapiere zu verstehen. Wir empfehlen Interessenten und potenziellen Anlegern den Basisprospekt und die Endgültigen Bedingungen zu lesen, bevor sie eine Anlageentscheidung treffen, um sich möglichst umfassend zu informieren, insbesondere über die potenziellen Risiken und Chancen des Wertpapiers. Sie sind im Begriff, ein Produkt zu erwerben, das nicht einfach ist und schwer zu verstehen sein kann.